Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 19, Issue 9, 1997, Pages 927-932

  Bacigalupo, A ^a   Soracco, M ^a   Vassallo, F ^a   Abate, M ^a   Van Lint, M T ^a   Gualandi, F ^a   Lamparelli, T ^a   Occhini, D ^a   Mordini, N ^a   Bregante, S ^a   Figari, O ^a   Benvenuto, F ^a   Sessarego, M ^b   Fugazza, G ^b   Carlier, P ^a   Valbonesi, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic myeloid leukemia; Donor lymphocyte infusions; Graft versus leukemia

Indexed keywords

AMINOTRANSFERASE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; APLASIA; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFUSION; LYMPHOCYTE; MALE; PRIORITY JOURNAL; RELAPSE; RISK;

EID: 0030920348     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700762     Document Type: Article

References (25)

1. Horowitz MM, Gale PB, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
2. Marmont AM, Gale RP, Butturini A et al. T-cell depletion in allogeneic bone marrow transplantation: progress and problems. Haematologica 1989; 74: 235-248.
3. Bortin MM, Truitt RL, Rimm AA et al. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 1979; 281: 490-491.
4. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with istoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155-159.
5. Barret AJ, Malkovska V. Graft-versus-leukemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754-761.
6. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC compatible bone marrow. Bone Marrow Transplant 1991; 8: 51-58.
7. Kolb HJ, Mittermuller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 12: 2462-2465.
8. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
9. Bar BMAM, Schattemberg A, Mensink EJBM et al. Donor lymphocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
10. Helg C, Roux E, Beris P et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplant 1993; 12: 125-129.
11. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after bone marrow transplantation. Efficacy and toxicity of a denned T-cell dose. Blood 1993; 82: 2310-2318.
12. Jiang YZ, Cullis JO, Kanfer EJ et al. T cell and NK cell mediated graft-versus-leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1993; 11: 133-138.
13. Hertenstein B, Wiesneth M, Novotny J et al. Interferon alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic marrow transplantation. Transplantation 1993; 56: 1114 (Abstr.).
14. Szer J, Grigg GL, Philips et al. Donor leukocyte infusion after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant 1993; 11: 109-111.
15. Slavin S, Naparstek N, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
16. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
17. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leucocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
18. Nimer SD, Giorgi J, Gajewski JL et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 1994; 57: 82-88.
19. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. New Engl J Med 1990; 323: 315-321; published erratum appears in New Engl J Med 1990; 323: 1360.
20. van Dijken PJ, Wimperis J, Crawford JM et al. Effect of graft-versus-host disease on hematopoiesis after bone marrow transplantation in mice. Blood 1991; 78: 2773-2779.
21. Gratwohl A, Hermans J, Baldomero H. Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1995; 17: 137-148.
22. Verfaule CM, Miller WJ, Boylan K et al. Selection of benign leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
23. Goulmy E. Minor histocompatibility antigens and their role in transplantation. Transplant Rev 1988; 2: 29-53.
24. Podesta M, Piaggio G, Frassoni F et al. Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myeloid leukemia (CML). Bone Marrow Transplant 1996; 16: 549-555.
25. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft-vs-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-vs-Host Disease. Immunology, Pathophysiology, and Treatment. Marcel Dekker: New York, Basel, 1990.